Navigation Links
Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic

AUSTIN, TX and TORONTO, March 4 /PRNewswire/ - Affinium Pharmaceuticals today announced that they have commenced the dosing of healthy subjects in a Phase I study of AFN-1252, one of its lead clinical candidates from its novel class of fatty acid biosyntheis inhibitors. The study of AFN-1252 will evaluate the safety, tolerability and pharmacokinetics of a single escalating oral dose. Affinium believes that AFN-1252 will provide patients and their doctors a potent, oral and IV treatment for susceptible and resistant staphylococcal infections both in and out of hospitals.

AFN-1252 is an investigational antibiotic, with a novel mechanism of action, and very high potency against all drug-resistant phenotpyes of staphylococci including hospital and community-acquired MRSA. Oral bioavailability has previously been demonstrated in a human microdosing study and excellent in vivo efficacy has been demonstrated in various animal models of infection.

"Affinium is very pleased to advance this novel class of antibiotics with great potential to address the serious unmet medical need for new oral and IV antibiotics capable of treating multi-drug resistant staphylococcal infections," said Dr. Barry Hafkin, Chief Medical Officer of Affinium Pharmaceuticals. "In preclinical studies, AFN-1252 was well tolerated at high multiples of the projected human dose in two species, suggesting a safety profile that would be very attractive to physicians practicing both in and out of hospital settings." Dr. Hafkin added that "the specific-spectrum of activity of AFN-1252 may provide further safety advantages by decreasing the risk of gut and cutaneous flora disruption."

About Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines. AFN-1252 utilizes a unique mechanism of action by directly inhibiting the function of the bacterial fatty acid synthesis (FAS) II pathway. Affinium's FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors of a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway and are not subject to resistance selection pressures caused by the use of existing broad spectrum antibiotics.

SOURCE Affinium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
2. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
3. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
4. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
5. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
6. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
7. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
8. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
9. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
10. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
11. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: